Group 1 - The core viewpoint of the article highlights that Yongxi Investment has conducted research on a listed company, Weili Medical, focusing on its strategies to expand overseas production in response to domestic medical consumables procurement and geopolitical risks [1] - Weili Medical is actively building a factory in Mexico starting in 2024, having completed land acquisition and project planning, while also preparing a second overseas production base in Indonesia to mitigate high tariffs imposed by the U.S. [1] - The company expects that by 2024, overseas business will account for approximately 54% of its total revenue, with North America contributing 34%, Europe 27%, Asia 15%, and South America 8% [1] Group 2 - Weili Medical has seen a significant increase in the gross profit margin of its overseas business, rising from 27% in 2021 to 35% in 2024, an increase of 8 percentage points [1] - The company is diversifying its export products, with a growing proportion of high-margin products being exported, which contributes to the overall improvement in gross profit margins [1]

证券研究报告：医药生物|行业周报 发布时间：2025-06-16 行业投资评级 强于大市 |维持 行业基本情况 | 收盘点位 | | 7895.79 | | --- | --- | --- | | 52 | 周最高 | 8490.25 | | 52 周最低 | | 6070.89 | 行业相对指数表现 2024-06 2024-08 2024-11 2025-01 2025-04 2025-06 -14% -11% -8% -5% -2% 1% 4% 7% 10% 13% 16% 19% 医药生物 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:蔡明子 SAC 登记编号:S1340523110001 Email:caimingzi@cnpsec.com 分析师:龙永茂 SAC 登记编号:S1340523110002 Email:longyongmao@cnpsec.com 近期研究报告 推荐标的：英科医疗、迈普医学、怡和嘉业、微电生理、 拱东医疗、派林生物、益丰药房、大参林、康臣药业、佐力药 业、桂林三金、天士力、新里程、美年健康、国际医学。 《政策支持上市公司通过并购重组高 质量发展，行业整合持 ...

Market Overview - On June 13, stock indices in China experienced a downward trend, with the Shanghai Composite Index falling below 3400 points, closing down 0.75% at 3377 points, while the Shenzhen Component Index and ChiNext Index dropped over 1% [1] - The total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 150.41 billion yuan, an increase of approximately 20 billion yuan compared to the previous day [1] - Sectors such as media, retail, liquor, automotive, pharmaceuticals, and real estate declined, while the oil sector surged [1] Military Trade Opportunities - The recent escalation of tensions in the Middle East, particularly Israel's airstrikes on Iran, has created new opportunities in the military trade market [2] - Global military spending is projected to increase for the tenth consecutive year in 2024, with the highest growth rates seen in Europe and the Middle East [2] - China's military exports are transitioning from low-end to high-end weaponry, with increasing international recognition of domestic military products [2] Oil Price Volatility - Current geopolitical tensions, particularly in the Middle East and Ukraine, are driving significant fluctuations in oil prices [3] - The next OPEC+ meeting on July 6 is crucial, as the group's production strategy may change in response to high oil prices [3] - Brent crude oil prices are expected to fluctuate between $70 and $100 per barrel in the short term, depending on demand and OPEC+ production levels [3] AI Industry Growth - As of May 2025, the daily usage of tokens for the Doubao large model exceeded 16.4 trillion, a growth of over 137 times since its launch last year [4] - Oracle anticipates a growth rate of over 40% for its overall cloud business in the 2026 fiscal year, with IaaS growth exceeding 70% [4] - The surge in AI-related activities indicates a high level of industry vitality, suggesting continued investment in the computing power supply chain [4] Medical Supplies Procurement Optimization - The State Council meeting on June 13 discussed optimizing drug and medical supplies procurement policies to enhance collaboration in the healthcare sector [5] - The meeting emphasized the need for better evaluation of procurement policies and improving the quality control of drugs and medical supplies [5][6] - Optimizing procurement rules is expected to benefit the medical supplies industry, particularly high-value supplies, by stabilizing market confidence [6] Real Estate Market Stabilization - The State Council meeting also focused on strategies to stabilize the real estate market, emphasizing the importance of a new development model [7] - Policies will be implemented to support the construction of quality housing and improve the overall effectiveness of existing policies [7] - The aim is to activate demand and optimize supply in the real estate sector to prevent further declines [7] Infrastructure Development - The "Two Heavy" construction projects are accelerating, focusing on national strategic implementation and safety capabilities [8] - Significant progress is being made in the construction of key railway and port projects, supported by various facilitation measures [8] Brain-Computer Interface Clinical Trials - China has successfully conducted its first prospective clinical trial of an invasive brain-computer interface, becoming the second country after the U.S. to enter this phase [9] Red-Chip Stock Listing in Shenzhen - New policies allow companies listed in Hong Kong to also list in Shenzhen, which is expected to enhance financial collaboration in the Guangdong-Hong Kong-Macau Greater Bay Area [10] - This initiative is anticipated to boost investor confidence in China's capital markets and facilitate the return of quality tech companies to the A-share market [10]

Core Viewpoint - The State Council emphasizes the need to strengthen the evaluation of drug and consumable procurement policies to ensure public confidence in medication [1] Group 1: Policy Evaluation and Implementation - The meeting highlighted the importance of summarizing experiences and addressing shortcomings in drug and consumable procurement policies [1] - There is a push for the standardization and institutionalization of procurement work to ensure its regular implementation [1] Group 2: Healthcare System Improvement - The meeting aims to better promote the coordinated development of the "three medical" systems (medical services, medical insurance, and pharmaceuticals) [1] - It calls for the improvement of public hospital compensation mechanisms to support the innovation capabilities of pharmaceutical companies [1] Group 3: Quality Control and Assurance - There is a focus on enhancing quality supervision across the entire chain of drug and consumable production, circulation, and usage [1] - The initiative includes advancing the consistency evaluation of the quality and efficacy of generic drugs to ensure public safety in medication [1]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index (Sci-Tech Medical, 950255) reported at 737.03 points, indicating a recent performance trend with a 1.84% increase over the past month, a 2.05% decrease over the past three months, and a 1.64% increase year-to-date [1] - The index comprises no more than 30 listed companies in the medical sector from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index is based on a reference date of December 30, 2022, with a base point of 1000.0 [1] Group 2 - The top ten weightings in the index are as follows: Huatai Medical (11.45%), United Imaging (10.09%), Aibo Medical (6.94%), Yirui Technology (6.44%), Nanwei Medical (5.44%), Shengxiang Biology (5.0%), Xinmai Medical (4.74%), Haier Biomedical (4.22%), Yahui Long (3.61%), and Aohua Endoscopy (3.52%) [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with a 100.00% representation [1] - The industry composition of the index holdings includes 45.39% in medical consumables, 33.24% in medical devices, and 21.37% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to calculation and maintenance guidelines [2]

Group 1 - The core viewpoint of the news is that the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index has shown mixed performance, with a recent increase of 1.89% over the past month, a decrease of 3.03% over the past three months, and a year-to-date increase of 1.35% [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (11.48%), United Imaging (10.13%), Aibo Medical (6.9%), Yirui Technology (6.49%), Nanwei Medical (5.37%), Shengxiang Biology (4.91%), Xinmai Medical (4.69%), Haier Biomedical (4.16%), Yahui Long (3.62%), and Aohua Endoscopy (3.59%) [1] - The index's holdings are entirely from the Shanghai Stock Exchange, with a 100% allocation [1] - The industry composition of the index holdings includes: medical consumables (45.40%), medical devices (33.27%), and in vitro diagnostics (21.34%) [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with temporary adjustments made under special circumstances [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to calculation and maintenance guidelines [2]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which reflects the overall performance of up to 30 listed companies in the medical sector on the Sci-Tech Innovation Board [1] - The Shanghai Sci-Tech Innovation Board Medical Index has increased by 2.43% in the past month, decreased by 2.53% in the past three months, and has risen by 1.89% year-to-date [1] - The index is based on a reference date of December 30, 2022, with a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (10.99%), United Imaging (10.25%), Aibo Medical (6.82%), Yirui Technology (6.61%), Nanwei Medical (5.29%), Shengxiang Biology (5.01%), Xinmai Medical (4.65%), Haier Biomedical (4.17%), Aohua Endoscopy (3.77%), and Yahui Long (3.65%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% allocation [1] - In terms of industry composition, medical consumables account for 44.80%, medical devices for 33.62%, and in vitro diagnostics for 21.58% [1] Group 3 - The index samples are adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - Companies that are delisted or undergo mergers, acquisitions, or splits will be handled according to the calculation and maintenance guidelines [2]

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2]. Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14]. - The pharmaceutical and biotechnology sector has shown a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18]. Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14]. - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15]. 2. Subsector Performance - The pharmaceutical sector's sub-indices all recorded gains, with the raw materials and blood products sectors leading with a 2.89% increase [7][22]. - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26]. 3. Recommended and Beneficiary Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihe Jiaye, among others [8]. - Beneficiary stocks identified are Shanhaishan, Yirui Technology, and Lianying Medical [27]. 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI applications in imaging and surgery [26]. - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29]. - **IVD Sector**: The report notes a 2.00% increase in the IVD sector, with a focus on AI-assisted diagnostics [30]. - **Blood Products**: The blood products sector is experiencing a 2.89% increase, with ongoing consolidation and product diversification [31]. - **Retail Pharmacy**: The offline pharmacy sector is expected to benefit from improved operational efficiencies through AI integration [34]. - **Healthcare Services**: The hospital sector has seen a 1.07% increase, with growth in specific medical fields like ophthalmology and reproductive health [36]. - **Traditional Chinese Medicine**: The sector is expected to recover as the impact of previous procurement policies diminishes [38]. - **CXO Sector**: The report indicates a positive outlook for the CXO sector, driven by increased demand for outsourcing in drug development [40].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Viewpoints - The report emphasizes that policy support for listed companies through mergers and acquisitions is crucial for high-quality development, leading to ongoing industry consolidation [5][14] - The pharmaceutical and biotechnology sector has seen a weekly increase of 1.13%, outperforming the CSI 300 index by 0.25 percentage points, ranking 17th among 31 sub-industries [7][18] Summary by Sections 1. Weekly Viewpoint - The report highlights that recent policies have improved regulatory inclusiveness and relaxed competition restrictions, facilitating mergers and acquisitions [14] - Companies like Maipu Medical and Pilin Bio have announced plans for mergers and acquisitions, which are expected to enhance their technological capabilities and market positions [6][15] 2. Subsector Performance - The pharmaceutical and biotechnology sector has shown positive performance across all sub-sectors, with the raw materials and blood products sectors leading with a 2.89% increase [7][22] - The report suggests that the medical device sector has significant room for valuation growth, with a current P/E ratio of 37.55, below its historical average [26] 3. Recommended and Benefiting Stocks - Recommended stocks include Yingke Medical, Maipu Medical, and Yihua Jiaye, among others [8] - Benefiting stocks from the current trends include Shanhaishan, Yirui Technology, and Lianying Medical [8][27] 4. Detailed Subsector Analysis - **Medical Devices**: The sector is expected to benefit from policies promoting equipment upgrades and procurement, with a focus on AI integration in imaging and surgical applications [26] - **Medical Consumables**: The sector is projected to see steady growth as high-value consumables approach the end of their procurement cycle [29] - **IVD Sector**: The in vitro diagnostics sector is anticipated to recover as AI technologies enhance diagnostic capabilities [30] - **Blood Products**: The blood products sector is experiencing stable demand, with a projected 10.9% increase in plasma collection in 2024 [31] - **Retail Pharmacy**: The retail pharmacy sector is expected to see improved performance as market conditions stabilize and AI technologies enhance operational efficiency [34] - **Healthcare Services**: The healthcare services sector is showing signs of recovery, particularly in ophthalmology and reproductive health services [36] - **Traditional Chinese Medicine**: The sector is expected to benefit from improved consumer sentiment and demand for high-quality OTC products [38] - **CXO Sector**: The CXO sector is entering an upward cycle as companies report improved order growth and performance [40]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has shown a 4.01% increase over the past month, a 0.74% decrease over the past three months, and a 1.94% increase year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huitai Medical (10.98%), United Imaging (10.82%), Aibo Medical (6.74%), Yirui Technology (6.5%), Nanwei Medical (5.36%), Shengxiang Biology (4.94%), Xinmai Medical (4.68%), Haier Biomedical (4.22%), Yahui Long (3.6%), and Aohua Endoscopy (3.4%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100.00% share [1] - The industry composition of the index holdings includes 45.00% in medical consumables, 33.89% in medical devices, and 21.10% in in vitro diagnostics [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the sample adjustments [2] - In special circumstances, the index may undergo temporary adjustments, such as when a sample company is delisted or undergoes mergers, acquisitions, or splits [2]